Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus Paclitaxel in Advanced Gastric/GEJ Cancer
NCT02178956Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Oct 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of napabucasin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sumitomo Pharma America. Started Oct 2014; status: completed.
02
Drugs
napabucasin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02178956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178956.